ProfileGDS5678 / 1417449_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 82% 81% 83% 83% 85% 84% 85% 86% 85% 85% 82% 83% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9252182
GSM967853U87-EV human glioblastoma xenograft - Control 25.9992582
GSM967854U87-EV human glioblastoma xenograft - Control 35.8480281
GSM967855U87-EV human glioblastoma xenograft - Control 46.2195983
GSM967856U87-EV human glioblastoma xenograft - Control 56.0809983
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1902785
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0589984
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3108385
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.4530386
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3704785
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2988785
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9354782
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0021783
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1217483